Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
&-
Good afternoon, everyone. Thanks for joining us here today. I'm [Richard Mayland] , and I'm an associate on the Healthcare Investment Banking team. It's my pleasure to introduce Madrigal Pharmaceuticals today. We're excited to be here with CEO, Bill Sibold. With that, Bill, I'll turn it over to you.
Thanks, Richard. It's a first of all, real pleasure to be here. I'd like to thank JPMorgan for having us. This is my first JPMorgan as the CEO of Madrigal, and it's an exciting time for us as we approach a March 14 due for date.
A very rare thing in the industry and to be able to be potentially the first product to be approved in NASH in the United States ever. It's a exciting time for us here forward looking statements, and I thought I would start here to really talk a little bit about the problem that we're trying to solve.
And NASH is a very I would say, poorly recognized disease and the severity of it.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
